RT Journal Article
SR Electronic
T1 Frequent shedding of multi-drug resistant pneumococci among adults living with HIV on suppressive antiretroviral therapy in Malawi
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.28.22281638
DO 10.1101/2022.10.28.22281638
A1 Sibale, Lusako
A1 Phiri, Joseph
A1 Mitole, Ndaona
A1 Kalata, Newton
A1 Nyazika, Tinashe
A1 Kalirani, Alice
A1 Khwiya, Mercy
A1 Sagawa, Gift
A1 Thindwa, Deus
A1 Swarthout, Todd D
A1 French, Neil
A1 Malisita, Ken
A1 Kamng’ona, Arox
A1 Ferreira, Daniela M
A1 Heyderman, Robert S.
A1 Kwambana-Adams, Brenda A.
A1 Jambo, Kondwani
YR 2022
UL http://medrxiv.org/content/early/2022/10/31/2022.10.28.22281638.abstract
AB People living with human immunodeficiency virus (PLHIV) on antiretroviral therapy (ART) are reported to have three times higher carriage of Streptococcus pneumoniae than their HIV-uninfected counterparts in point prevalence studies. Using a longitudinal cohort study design, we assessed pneumococcal carriage density, shedding and antibiotic resistance profiles, as well as nasal mucosal immunity, in otherwise healthy PLHIV on ART for at least one year, compared to HIV-uninfected participants in Malawi. Pneumococcal carriage density was higher among PLHIV compared to HIV-uninfected participants. Moreover, PLHIV were twice more likely to shed pneumococci than HIV-uninfected participants. In PLHIV, aerosol shed pneumococci were more often multi-drug resistant (MDR) than nasopharyngeal carried isolates recovered from the same individual. Consistent with high shedding, PLHIV exhibited heightened neutrophil-mediated nasal mucosa inflammation. We propose that PLHIV should be considered in intervention strategies, such as vaccination, as they could be an important reservoir for transmission of MDR S. pneumoniae.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute for Health Research (NIHR) [16/136/46]. KCJ is supported by an MRC African Research Leader award [MR/T008822/1]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:College of Medicine Research Ethics Committee (COMREC) of the Kamuzu University of Health Sciences (P.11/18/2532) and Liverpool School of Tropical Medicine Research Ethics Committee (LSTMREC) (19-033) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors